Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 5/20 | 0.42 |
| ▸ | DRD4 | P21917 | 4/20 | 0.42 |
| ▸ | HTR1A | P08908 | 7/20 | 0.42 |
| ▸ | HTR1D | P28221 | 6/20 | 0.42 |
| ▸ | HTR1B | P28222 | 5/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.42 |
| ▸ | HTR2A | P28223 | 2/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.40 |
| ▸ | DRD3 | P35462 | 3/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1223298 | 1.00 | DRD2 (0.42) | DRD2DRD4HTR1AHTR1DHTR1B | |
| SCHEMBL1224492 | 0.97 | HTR1A (0.40) | DRD2DRD4HTR1AHTR1DHTR1B | |
| SCHEMBL1224494 | 0.97 | HTR1A (0.40) | DRD2DRD4HTR1AHTR1DHTR1B | |
| SCHEMBL1224569 | 0.88 | KCNH2 (0.44) | KCNH2 | |
| SCHEMBL1224571 | 0.88 | KCNH2 (0.44) | KCNH2 | |
| SCHEMBL1223525 | 0.87 | KCNH2 (0.50) | KCNH2 | |
| SCHEMBL1224083 | 0.87 | KCNH2 (0.50) | KCNH2 | |
| SCHEMBL1223721 | 0.87 | KCNH2 (0.50) | KCNH2 | |
| SCHEMBL632789 | 0.87 | KCNH2 (0.43) | HTR1ASIGMAR1KCNH2 | |
| SCHEMBL632790 | 0.87 | KCNH2 (0.43) | HTR1ASIGMAR1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2905283-B1 | Oxazolidinone antibiotics | ACTELION PHARMACEUTICALS LTD (CH) | 2016-12-14 | — | — | EP | claimed |
| EP-2905283-A1 | Oxazolidinone antibiotics | Actelion Pharmaceuticals Ltd. (CH) | 2015-08-12 | — | — | EP | claimed |
| US-8217029-B2 | Oxazolidinone antibiotics | ACTELION PHARMACEUTICALS LTD (CH) | 2012-07-10 | — | — | US | claimed |
| US-20110039823-A1 | OXAZOLIDINONE ANTIBIOTICS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-02-17 | — | — | US | claimed |
| EP-2905283-B1 | Oxazolidinone antibiotics | ACTELION PHARMACEUTICALS LTD (CH) | 2016-12-14 | — | — | EP | disclosed |
| EP-2915813-A1 | Oxazolidinone antibiotics | Actelion Pharmaceuticals Ltd. (CH) | 2015-09-09 | — | — | EP | disclosed |
| EP-2905283-A1 | Oxazolidinone antibiotics | Actelion Pharmaceuticals Ltd. (CH) | 2015-08-12 | — | — | EP | disclosed |
| US-8217029-B2 | Oxazolidinone antibiotics | ACTELION PHARMACEUTICALS LTD (CH) | 2012-07-10 | — | — | US | disclosed |
| US-20110039823-A1 | OXAZOLIDINONE ANTIBIOTICS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039823-A1 | OXAZOLIDINONE ANTIBIOTICS | OXA1L, XDH, UBE2D3 | DRD2 78/4885DRD4 60/4885HTR1A 4255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.